Hints and tips:
Related Special Reports
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
...The abandoned asundexian trial “is a major setback for Bayer”, said Markus Manns, a portfolio manager and healthcare expert at Union Investment, Germany’s third-largest asset manager....
...Metagenomi, a pre-clinical group backed by Moderna and Bayer, priced its $94mn IPO last week at the bottom of its target range, and fell 31 per cent on its first day of trading on Friday....
...They produce prescription drugs against cancer, heart disease and other illness, over-the-counter healthcare products like Bepanthen cream as well as seeds and herbicides for farmers....
...Bayer has said it is shifting the focus of its pharmaceutical business to the US and away from Europe and the UK, where governments are making “big mistakes” in how they manage health budgets....
...healthcare and crop science....
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
...Meanwhile, Germany’s Bayer in January said it was cutting jobs in Britain because of the UK medicines levy....
...Consider Rajah & Tann’s work for Bayer on the use of drones. The pharmaceutical and chemicals conglomerate uses drones to help farmers in south-east Asia access more accurate and useful weather data....
...The pharmaceutical giants AbbVie and Eli Lilly have pulled out of the UK’s pricing agreement with the NHS. Bayer’s pharmaceutical arm is reducing its UK footprint and cutting jobs....
...of pharmaceuticals for the Americas....
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
...Bayer, which is headquartered in Germany, told the Financial Times it will shift the focus of its pharmaceutical business to the US, accusing Europe of being “very innovation unfriendly”....
...Some in the medical sector are sceptical that AI drug discovery will fulfil its hype, pointing to the need to navigate strict regulations and integrate into dated healthcare systems....
...Bayer shuns ‘innovation unfriendly’ Europe The German pharmaceutical company has said it is shifting the focus of its drugs business to the US and away from Europe, where governments are making “big mistakes...
...Paul Hastings O: 6; L: 7; I: 7; Total: 20The firm advised South Korean pharmaceutical company SD Biosensor and South Korean private equity fund SJL Partners on the acquisition of US-listed pharmaceutical...
...Accordingly, big pharma groups like Pfizer, Bayer and Regeneron have taken note, forming partnerships with the pioneers....
...“Supply chains have broken down because of the fighting and there is an urgent need to get healthcare supplies to people under siege,” said Pasko, who is liaising with healthcare vendors, logistics companies...
...of healthcare and the pharmaceutical sectors....
...Bayer’s pharmaceuticals business in 2020 generated 42 per cent of the group’s revenue but 52 per cent of its operating profit before exceptional items....
...The Russian Direct Investment Fund, the Kremlin’s state wealth fund that has financed the Gamaleya Institute’s Sputnik V vaccine, declined to comment on the Mexico trials but said approval by national healthcare...
...Other rivals include consumer groups Procter & Gamble, Colgate, Reckitt Benckiser and Nestlé, and drugmakers Bayer and Sanofi, while cheaper private-label products also command a chunk of the market....
...Anvisa, the country’s healthcare and medicines watchdog, cited risks with Sputnik V and said there was not enough information about its safety, effectiveness and quality....
...Its three biggest rivals are also pharmaceutical companies — Johnson & Johnson, Bayer and Sanofi — but healthcare has been an area of growth for consumer goods companies such as Reckitt Benckiser and Procter...
International Edition